Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Cancer Imaging and Image-directed Interventions

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1486495

Prognostic Significance of FDG-PET/CT based Radiomics Analysis in Newly-diagnosed Multiple Myeloma: A Comparative Study with Clinical Assessment Authors' information

Provisionally accepted
Fei  LiFei Li1Baiyang  JiangBaiyang Jiang2Ye  FuYe Fu2Qingyang  YuQingyang Yu2Guangwen  DuanGuangwen Duan2Jiayang  YanJiayang Yan2Qinling  JiangQinling Jiang2Hongbiao  SunHongbiao Sun2Yi  XiaoYi Xiao2Qi  ChenQi Chen3Shaochun  XuShaochun Xu2*Xiang  WangXiang Wang2*Shiyuan  LiuShiyuan Liu2*
  • 1Shanghai United Imaging Intelligence, Co., Ltd., Shanghai, China
  • 2Department of Radiology, Shanghai Changzheng Hospital, Shanghai, China
  • 3Department of Radiology, Kunshan Third People’s Hospital, Kunshan, China

The final, formatted version of the article will be published soon.

This study aimed to construct and validate a fusion diagnostic model based on Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography(FDG-PET/CT) radiomics for predicting overall survival of multiple myeloma (MM) patients.A total of 199 patients newly diagnosed with MM were included from two centers. All patients underwent whole-body PET/CT scans within one month before the initiation of treatment and were followed up for over five years. Radiomic features of MM were extracted from CT images and dimensionality reduction was performed by LASSO regression analysis. Cox Proportional Hazards Model was then constructed to predict patient survival. A clinical-radiomic fusion model was constructed by integrating independent clinical risk factors, including comprehensive laboratory parameters, R-ISS, and PET functional metabolic parameters, with the radiomic model. The discrimination ability of the model was evaluated using the C-index, and it's calibration was assessed using calibration curves.The C-indexes for the radiomics model in the training and testing cohorts were 0.736 and 0.708, respectively; for the clinical model, they were 0.676 and 0.696, respectively; and for the integrated model, they were 0.791 and 0.776, respectively. The integrated diagnostic model outperformed both the radiomics and clinical models, showcasing higher discriminative ability and improved calibration. In the training set, the C-index was 0.791 (95% confidence interval [CI]: 0.713-0.853), with an ICI of 0.015, E50 of 0.014, and AIC of 10.987. In the testing set, the C-index was 0.776 (95% CI: 0.654-0.894), with an ICI of 0.069, E50 of 0.04, and AIC of 11.492.This integrated prediction model exhibited satisfactory performance in predicting survival outcomes for patients diagnosed with MM and improved precision in discriminating between patients with a good prognosis and poor prognosis.

Keywords: Multiple Myeloma, Radiomics, 18-FDG PET/CT, computer-aided diagnosis, Prognostic value

Received: 29 Aug 2024; Accepted: 29 Jul 2025.

Copyright: © 2025 Li, Jiang, Fu, Yu, Duan, Yan, Jiang, Sun, Xiao, Chen, Xu, Wang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Shaochun Xu, Department of Radiology, Shanghai Changzheng Hospital, Shanghai, China
Xiang Wang, Department of Radiology, Shanghai Changzheng Hospital, Shanghai, China
Shiyuan Liu, Department of Radiology, Shanghai Changzheng Hospital, Shanghai, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.